Medtronic, Inc. announced that it will be completing the study of Endeavor Resolute by December 2011.

Endeavor Resolute is cobalt chromium coronary stent which has thinner struts and provides greater maneuverability. It is designed to treat patients who are at higher clinical risk of target lesion evascularisation (TLR). Endeavor Resolute combines the proven drug and stent components of Endeavor with Biolinx, a biocompatible polymer specifically engineered for drug-eluting stent use. Biolinx facilitates the slower absorption of Zotarolimus while providing excellent biocompatibility. The design goal of Endeavor Resolute is enhanced safety and efficacy in the most complex lesions and patients.

To evaluate the clinical safety, efficacy, and pharmacokinetics (PK) of the Endeavor Resolute Zotorolimus Eluting Coronary Stent System for the treatment of single de novo lesions in native coronary arteries with a reference vessel diameter (RVD) between 2.5 and 3.5 mm in diameter.

This 139 patient, phase II study is ongoing, but not recruiting participants. The official title of the study is “The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions”.